MiNK Therapeutics/$INKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Ticker
$INKT
Sector
Primary listing
Employees
23
Headquarters
Website
INKT Metrics
BasicAdvanced
$55M
-
-$2.93
0.35
-
Price and volume
Market cap
$55M
Beta
0.35
52-week high
$76.00
52-week low
$6.34
Average daily volume
593K
Financial strength
Current ratio
1.063
Quick ratio
1.025
Total debt to equity
-36.404
Profitability
EBITDA (TTM)
-12.46
Management effectiveness
Return on assets (TTM)
-79.17%
Return on equity (TTM)
73.90%
Valuation
Price to book
-3.65
Price to tangible book (TTM)
-3.65
Price to free cash flow (TTM)
-7.957
Free cash flow yield (TTM)
-12.57%
Free cash flow per share (TTM)
-1.387
Growth
Earnings per share change (TTM)
2.36%
3-year earnings per share growth (CAGR)
-29.40%
INKT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiNK Therapeutics stock?
MiNK Therapeutics (INKT) has a market cap of $55M as of April 13, 2026.
What is the P/E ratio for MiNK Therapeutics stock?
The price to earnings (P/E) ratio for MiNK Therapeutics (INKT) stock is 0 as of April 13, 2026.
Does MiNK Therapeutics stock pay dividends?
No, MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders as of April 13, 2026.
When is the next MiNK Therapeutics dividend payment date?
MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders.
What is the beta indicator for MiNK Therapeutics?
MiNK Therapeutics (INKT) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.